On Nov 05, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $5 to $12.
Barclays analyst Gena Wang maintains with a hold rating, and adjusts the target price from $7 to $5.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and adjusts the target price from $9 to $7.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
RBC Capital analyst Luca Issi maintains with a hold rating, and adjusts the target price from $8 to $5.
Raymond James analyst Steven Seedhouse downgrades to a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The recent quarterly update from Editas Medicine was seen as incremental after the company's strategic revision, an analyst noted to investors.
The emphasis by Editas Medicine on in vivo HSPC editing is viewed by analysts as a strategic utilization of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update slated for the first quarter of 2025, alongside developments on reni-cel BD activity.
The recent quarter is viewed as incremental following the strategic shift that was recently announced. Editas Medicine has shifted its focus towards partnering or out-licensing its leading asset for SCD/BT, centering attention on the in vivo pipeline. This move is deemed a sound strategy given the gradual adoption observed thus far for the class. Nevertheless, a position of watchfulness is maintained, pending additional advancements in the in vivo pipeline.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
